12:00 AM
 | 
Apr 08, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Alpha tocotrienol quinone: Phase IIa started

Edison began a double-blind, placebo-controlled Phase IIa trial to evaluate 15 mg/kg EPI-743 thrice daily in about 20 female patients aged <18 years. Last month, Edison granted...

Read the full 111 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >